These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 15183497)

  • 21. Bladder and rectal toxicity of BeamCath application in radiotherapy of prostate cancer.
    Hanssen S; Norum J
    Anticancer Res; 2008; 28(5B):2865-8. PubMed ID: 19031926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer.
    Defraene G; Van den Bergh L; Al-Mamgani A; Haustermans K; Heemsbergen W; Van den Heuvel F; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1233-42. PubMed ID: 21664059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer.
    Marzi S; Arcangeli G; Saracino B; Petrongari MG; Bruzzaniti V; Iaccarino G; Landoni V; Soriani A; Benassi M
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):41-9. PubMed ID: 17276615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In regard to Trofimov et al.: Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison (Int J Radiat Oncol Biol Phys 2007;69:444-453).
    Albertini F; Lomax AJ; Hug EB
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1333-4; author reply 1334-5. PubMed ID: 17967323
    [No Abstract]   [Full Text] [Related]  

  • 25. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer.
    Fiorino C; Sanguineti G; Cozzarini C; Fellin G; Foppiano F; Menegotti L; Piazzolla A; Vavassori V; Valdagni R
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):953-62. PubMed ID: 14575825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer.
    van der Laan HP; van den Bergh A; Schilstra C; Vlasman R; Meertens H; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1138-45. PubMed ID: 17931794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In regards to Thames et al.: increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (Int J Radiat Oncol Biol Phys 2006;65:975-981).
    Pickles T; Williams SG
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):318-9; author reply 319. PubMed ID: 17189080
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.
    Lee CM; Lee RJ; Handrahan DL; Sause WT
    Urology; 2005 Jan; 65(1):114-9. PubMed ID: 15667875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In regard to Anagnostopoulos et al.: In vivo thermoluminescence dosimetry dose verification of transperinal (192)Ir high dose rate brachytherapy using CT-based planning for the treatment of prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:1183-1191).
    Duggan L; Bucci J; Kron T
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):911; author reply 911-2. PubMed ID: 15183495
    [No Abstract]   [Full Text] [Related]  

  • 32. Dose-volume histogram parameters and late side effects in magnetic resonance image-guided adaptive cervical cancer brachytherapy: in regard to Georg et al. (Int J Radiat Oncol Biol Phys 2011;79:356-362).
    Shi M; Wei L
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):315; author reply 315-6. PubMed ID: 21816293
    [No Abstract]   [Full Text] [Related]  

  • 33. [Genitourinary and rectal toxicity after radiation therapy for prostate cancer].
    Akimoto T; Saito J; Kitamoto Y
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():255-60. PubMed ID: 12599581
    [No Abstract]   [Full Text] [Related]  

  • 34. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Principal component, Varimax rotation and cost analysis of volume effects in rectal bleeding in patients treated with 3D-CRT for prostate cancer.
    Bauer JD; Jackson A; Skwarchuk M; Zelefsky M
    Phys Med Biol; 2006 Oct; 51(20):5105-23. PubMed ID: 17019028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of high- and low-source strength (125)I prostate seed implants: In regard to Narayana et al. (Int J Radiat Oncol Biol Phys 2005;61:44-51).
    Moerland MA; Battermann JJ
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):941-2. PubMed ID: 15936582
    [No Abstract]   [Full Text] [Related]  

  • 37. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure. A potential for increasing the benefit/risk ratio.
    Hille A; Töws N; Schmidberger H; Hess CF
    Strahlenther Onkol; 2005 Dec; 181(12):789-95. PubMed ID: 16362789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comment on dose escalation and biochemical failure in prostate cancer: in regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70:67-74).
    Schulz RJ; Kagan AR
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1288; author reply 1288-9. PubMed ID: 18572089
    [No Abstract]   [Full Text] [Related]  

  • 39. Commentary on dose escalation and biochemical failure in prostate cancer: in regard to Eade et al. (Int. J. Radiat. Oncol. Biol. Phys. 2007;68:682-689).
    Schulz RJ; Kagan AR
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):645; author reply 645-6. PubMed ID: 18207038
    [No Abstract]   [Full Text] [Related]  

  • 40. In regard to Kupelian et al.: Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seed/external beam radiotherapy for stage T1-T2 prostate cancer (Int J Radiat Oncol Biol Phys 2004;58:25-33).
    Halperin RM
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):631-2; author reply 632. PubMed ID: 15667989
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.